Rivaroxaban versus Warfarin in Treatment of Acute Lower Limb Deep Venous Thrombosis and its Affection on Quality of Life. | ||
| Ain Shams Journal of Surgery | ||
| Volume 17, Issue 4, October 2024, Pages 300-308 PDF (408.94 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ASJS.2024.306965.1151 | ||
| Authors | ||
| Ahmed Gamil Abdellattif* 1; Kirolos Shehata1; Abdelrahman Farrag2; Tarek A AbdelAzim3; Khaled Shawky4 | ||
| 1Department of Vascular Surgery, Faculty of Medicine, Cairo University, Egypt | ||
| 2Department of Vascular Surgery, Faculty of Medicine, Ain Shams University, Egypt | ||
| 3Department of Vascular Surgery, Armed Forces College of Medicine, Egypt | ||
| 4Department of Vascular Surgery, Faculty of Medicine, Beni Suef University, Egypt | ||
| Abstract | ||
| Background: Deep vein thrombosis (DVT) poses a considerable burden on the affected patients, which triggers the need for proper management and follow-up. This study aimed to evaluate the outcome of rivaroxaban versus warfarin in the treatment of patients with acute lower limb DVT. Patients and methods: This is a randomized controlled trial that included patients with ultrasound-proved acute lower limb DVT. Patients were equally randomized to Group A (Treated with warfarin) and Group B (treated with rivaroxaban). All patients received scheduled follow-up visits up to 6 months post-treatment, during which they received clinical examination, routine laboratory analysis, and duplex ultrasound. Results: Eighty patients were eligible to the study and enrolled in the two study groups. At the 6-month follow-up, the median (IQR) recanalization rate was 100.0% (87.5%–100.0%) in Group A and 100.0% (90.0%–100.0%) in Group B (P = 0.464). Valve incompetence was evident in eight patients in Group A (20.0%) and four patients in Group B (10.0%) (p = 0.211). The Villalta Score (VS) median (IQR) values were 2 (1–3) in Group A and 1 (0–3.5) in Group B (P = 0.340). Regression analysis demonstrated that predictors of 6-month post-thrombotic syndrome (PTS) were the patients’ age (OR = 1.46, p = 0.014) and dyslipidemia (OR = 11.6, p = 0.014). Conclusion: This study highlights the potential benefits of rivaroxaban over warfarin in the management of DVT, with trends suggesting better recanalization rates, lower valve incompetence, and a reduced Villalta score. | ||
| Keywords | ||
| Deep venous thrombosis (DVT); Warfarin; Rivaroxaban; recanalization; post-thrombotic syndrome (PTS) | ||
|
Statistics Article View: 149 PDF Download: 138 |
||
